Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 18
2014 41
2015 56
2016 89
2017 98
2018 158
2019 358
2020 564
2021 618
2022 558
2023 473
2024 157

Text availability

Article attribute

Article type

Publication date

Search Results

3,187 results

Results by year

Filters applied: . Clear all
Page 1
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology.
Naidoo J, Murphy C, Atkins MB, Brahmer JR, Champiat S, Feltquate D, Krug LM, Moslehi J, Pietanza MC, Riemer J, Robert C, Sharon E, Suarez-Almazor ME, Suresh K, Turner M, Weber J, Cappelli LC. Naidoo J, et al. J Immunother Cancer. 2023 Mar;11(3):e006398. doi: 10.1136/jitc-2022-006398. J Immunother Cancer. 2023. PMID: 37001909 Free PMC article.
Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering.
Michels KR, Sheih A, Hernandez SA, Brandes AH, Parrilla D, Irwin B, Perez AM, Ting HA, Nicolai CJ, Gervascio T, Shin S, Pankau MD, Muhonen M, Freeman J, Gould S, Getto R, Larson RP, Ryu BY, Scharenberg AM, Sullivan AM, Green S. Michels KR, et al. J Immunother Cancer. 2023 Mar;11(3):e006292. doi: 10.1136/jitc-2022-006292. J Immunother Cancer. 2023. PMID: 36918221 Free PMC article.
Neuroblastoma: an ongoing cold front for cancer immunotherapy.
Kennedy PT, Zannoupa D, Son MH, Dahal LN, Woolley JF. Kennedy PT, et al. J Immunother Cancer. 2023 Nov 22;11(11):e007798. doi: 10.1136/jitc-2023-007798. J Immunother Cancer. 2023. PMID: 37993280 Free PMC article. Review.
Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures.
Wei F, Azuma K, Nakahara Y, Saito H, Matsuo N, Tagami T, Kouro T, Igarashi Y, Tokito T, Kato T, Kondo T, Murakami S, Usui R, Himuro H, Horaguchi S, Tsuji K, Murotani K, Ban T, Tamura T, Miyagi Y, Sasada T. Wei F, et al. J Immunother Cancer. 2023 Jul;11(7):e006788. doi: 10.1136/jitc-2023-006788. J Immunother Cancer. 2023. PMID: 37433717 Free PMC article.
3,187 results